Numinus and cybin embark on a groundbreaking journey: pioneering phase 3 trials for major depressive disorder

Vancouver, british columbia--(newsfile corp. - may 30, 2024) - in a significant stride towards transforming mental health care, numinus wellness inc. (tsx: numi) (otcqx: numif) (fse: lr23) has proudly announced that its research site, cedar clinical research (ccr), has been selected for cybin's phase 3 pivotal multinational clinical trial of cyb003. aimed at revolutionizing the treatment of major depressive disorder (mdd), this collaboration marks a pivotal moment in the journey toward understanding and treating one of the most debilitating mental health conditions affecting over 20 million americans.
CYBN Ratings Summary
CYBN Quant Ranking